Galapagos is a clinical stage biotech company focused on developing novel medicines.  Headquartered in Belgium, the Company employs over 820 people and has been profitable the last two years with 2010 revenues of €136 million.

Galapagos’ most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases.

• Learn more about GLPG0634’s selective JAK1 profile
• View the webcast presentation for GLPG0634